Top priority projects
The following projects are top-priority activities, and Daiichi Sankyo is placing a strong emphasis on their successful execution.
Edoxaban is an oral anticoagulant that directly inhibits blood coagulation factor Xa. It is being developed with the goal of preventing venous thromboembolism such as pulmonary embolism, which is often associated with “travelers’ thrombosis,” as well as postsurgical thromboembolism. Daiichi Sankyo is itself developing Edoxaban globally in the United States, Europe and Japan as well as other Asian countries. In addition to conducting multinational phase III trials for the prevention of thromboembolic events in patients with atrial fibrillation and phase III trials in Japan for the prevention of post-surgery thromboembolic events, the company began multinational phase III trials for the prevention of venous thromboembolic events in patients with deep vein thrombosis and pulmonary embolism in February 2010.
AMG 162 (Denosumab, an Anti-RANKL Antibody)
Denosumab is a fully human monoclonal antibody that specifically inhibits RANK ligand, a key mediator of the cells that break down bone. The anti-body is being developed to treat such conditions as osteoporosis and bone metastases of cancer. Having obtained exclusive development and marketing rights in Japan for AMG 162 from Amgen Inc. in July 2007, Daiichi Sankyo is now conducting phase III trials in Japan for the indication of osteoporosis as well as participating in multinational phase III trials for the indication of bone metastases.